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Background: A formulation of crush-resistant extended-release opioids may deter abuse. The 
purpose of this study was to evaluate the bioequivalence of oxymorphone extended-release 
(Oxy-ER) and a crush-resistant formulation of oxymorphone extended-release (Oxy-CRF).
Methods: In three open-label, randomized studies, healthy adults at a clinical research center 
received two single oral doses of Oxy-ER and two single doses of Oxy-CRF, each separated by 
a $7-day washout. Doses were administered under fasted conditions (study 1, 5 mg doses; study 
2, 40 mg doses) or after a high-fat breakfast (study 3, 40 mg doses). Subjects administered 40 mg 
doses also received naltrexone. The primary endpoint was systemic oxymorphone exposure; the 
bioequivalence criterion was met if the 90% confidence intervals of the geometric mean ratio 
(Oxy-CRF/Oxy-ER) for oxymorphone area under the curve from time 0 to the last measured 
concentration (AUC0–t), AUC from time 0 to infinity (AUC0–inf), and maximum plasma concen-
tration (Cmax) were within 0.8–1.25. Safety was assessed by monitoring adverse events.
Results: In studies 1, 2, and 3, the safety population comprised 30, 37, and 36 subjects and the 
pharmacokinetics population comprised 27, 30, and 29 subjects, respectively. Oxy-ER and Oxy-
CRF produced similar mean ± standard deviation oxymorphone AUC0–t (study 1, 5.05 ± 1.55 
versus 5.29 ± 1.52 ng ⋅ h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng ⋅ h/mL; study 3, 
50.16 ± 14.91 versus 49.01 ± 14.03 ng ⋅ h/mL) and Cmax (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 
2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions. 
The 90% confidence intervals for plasma oxymorphone AUC0–t, AUC0–inf, and Cmax fulfilled the 
bioequivalence criterion. Adverse event rates were similar with Oxy-ER and Oxy-CRF (study 
1, 25% versus 23%; study 2, 9% versus 16%; study 3, 20% each group).
Conclusion: Oxy-CRF and Oxy-ER (5 mg and 40 mg) are bioequivalent under fasted and 
fed conditions, suggesting that Oxy-CRF will have clinical efficacy and safety equivalent to 
Oxy-ER.
Keywords: abuse deterrent, bioequivalence, opioid, oxymorphone, pharmacokinetics, 
  substance abuse
Introduction
Between 1997 and 2006, the use of therapeutic opioids (mg/person) in the United States 
increased by 347%.1 Illicit opioid use, as with therapeutic use, has increased rapidly 
in the last decade. Between 1999 and 2006, the number of individuals reporting past-
month illicit use of pain relievers increased from 2,621,000 to 5,220,000.1
Abuse of extended-release opioids is a particular concern because of the potential 
for fatal doses to be released if a tablet is crushed or chewed. A survey of prescrip-
tion drug abusers entering drug rehabilitation found that 80% of abusers crush or 
chew extended-release opioids in order to abuse them.2 Chewing or crushing can Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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also occur without intention of abuse in patients who have 
difficulty swallowing intact tablets and do not understand 
the consequences of misusing their medication in this way. 
Formulation of extended-release tablets that are resistant to 
crushing and accidental chewing may deter abuse and prevent 
adverse events from misuse. Careful patient selection and 
adherence monitoring are also essential.3,4
Oxymorphone extended-release (Oxy-ER; Opana® ER, 
Endo Pharmaceuticals Inc, Chadds Ford, PA) is indicated 
for the relief of moderate to severe pain in patients requir-
ing continuous, around-the-clock opioid treatment for an 
extended period.5
We report three randomized clinical studies evaluating 
the bioequivalence of Oxy-ER and a crush-resistant for-
mulation of oxymorphone extended-release (Oxy-CRF; 
EN3288®, Endo Pharmaceuticals Inc, Chadds Ford, PA) 
at the highest (40 mg) and lowest (5 mg) supplied dosage 
strengths in healthy adults. Oxy-ER is formulated using 
TIMERx®   technology that minimizes fluctuation in drug 
concentrations, providing consistent 12-hour dosing,6 
which is advantageous in the setting of chronic pain. Oxy-
CRF contains oxymorphone embedded in a hard polymer 
matrix (distinct from TIMERx®) that is intended to be 
crush-  resistant. In vitro dissolution analyses of Oxy-ER and 
Oxy-CRF indicated that oxymorphone release from these 
formulations was not increased in 40% aqueous ethanol com-
pared with 0% ethanol.7 It was hypothesized that Oxy-ER 
and Oxy-CRF would produce equivalent systemic plasma 
oxymorphone exposure.
Methods
study design
Three open-label, randomized, single-dose, replicate, cross-
over studies were conducted at one site in the United States. 
In each study, healthy adults received two single doses of 
Oxy-ER and two single doses of Oxy-CRF during four alter-
nating treatment periods according to one of two randomly 
assigned sequences. In study 1, subjects were administered 
5 mg doses under fasted conditions; in study 2, subjects 
were administered 40 mg doses under fasted conditions; 
in study 3, subjects were administered 40 mg doses after a 
high-fat meal.
The studies were conducted in accordance with the 
Declaration of Helsinki, the International Conference on 
Harmonisation Good Clinical Practice, and US Food and 
Drug Administration regulations. The protocol and informed 
consent form were reviewed and approved by the institutional 
review board (Independent Investigational Review Board Inc, 
Plantation, FL), and all subjects provided written informed 
consent before participating.
subjects
Healthy men and women aged 18–45 years with a body mass 
index of 18.5–30 kg/m2 and no history of disease or clinically 
significant findings on physical or laboratory examination 
were eligible to participate. Women of childbearing potential 
were required to practice abstinence or use an acceptable 
method of birth control. Exclusion criteria were smoking, 
pregnancy, breast-feeding, allergy or hypersensitivity to 
opioids or naltrexone; a disease or condition that might 
interfere with drug absorption, distribution, metabolism, or 
excretion, or otherwise put a subject at risk; positive screen 
for substances of abuse, recent history of alcohol abuse, drug 
abuse, or significant mental illness, human immunodeficiency 
virus or hepatitis; recent (#14 days) use of other medication, 
except hormonal contraception, and use of medication known 
to affect hepatic drug metabolism in the past 30 days.
Treatment
Subjects received two single oral doses of 5 mg or 40 mg 
Oxy-ER and two single oral doses of Oxy-CRF, each dose 
separated by a $7-day washout. Doses were administered 
with 240 mL of room temperature water that subjects were 
instructed to drink in its entirety. Medication was admin-
istered according to one of two treatment sequences with 
alternating treatment periods (ABAB or BABA) based on a 
computer-generated randomization schedule. During each 
treatment period, subjects were confined to the study unit 
from one day before dosing through 48 hours postdose. All 
medication was administered under supervision by study 
personnel, and treatment compliance was verified by a mouth 
and hand check.
Subjects treated under fasted conditions underwent 
a $8-hour (40 mg doses) or $10-hour (5 mg doses) over-
night fast before drug administration and continued to fast 
through 4 hours after drug administration. Subjects treated 
under fed conditions underwent a $10-hour overnight fast 
followed by a high-fat meal (two eggs fried in butter, two 
strips of bacon, two slices of toast with butter, 4 oz hash 
brown potatoes, and 8 oz whole milk) initiated 30 minutes 
before drug administration. Subjects were instructed to eat 
the entire meal in #30 minutes.
To limit the potential for opioid-related adverse events, 
subjects who were administered 40 mg doses received 
three single doses of naltrexone 50 mg during each treat-
ment period (12 doses in all). Dosing occurred 12 and Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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2 hours before and 12 hours after each dose of Oxy-ER and 
  Oxy-CRF. Subjects not tolerating the two initial doses during 
the first treatment period were not randomized to treatment. 
Naloxone was readily available to all subjects in the event 
of respiratory depression.
Assessments
Pharmacokinetics
During each treatment period, blood samples for pharma-
cokinetic analysis were collected predose (#1 hour before 
drug administration) and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 
16, 24, 36, and 48 hours after drug administration. Samples 
were kept frozen at −70°C until analysis.   Oxymorphone and 
6-hydroxy-oxymorphone (6-OH-oxymorphone) concentra-
tions were determined using a simultaneous liquid chroma-
tography-tandem mass spectrometry method validated for the 
range of 0.025–10.00 ng/mL. Pharmacokinetic parameters 
(area under the concentration versus time curve from time 0 
to infinity [AUC0–inf], AUC from time 0 to the last measured 
concentration [AUC0–t], maximum plasma concentration 
[Cmax], and time to Cmax [tmax]) were derived from the plasma 
concentration data using noncompartmental methods and 
actual sample times. AUC0–t was calculated using the linear 
trapezoid rule, and AUC0–inf was calculated as AUC0–t plus 
last measured plasma concentration/terminal rate constant. 
The terminal rate constant (λz) was calculated by linear 
regression of the terminal portion of the linear concentra-
tion versus time curve, and the terminal half-life [t1/2] was 
calculated as ln 2/λz.
safety
Subjects were monitored for adverse events from one day 
before treatment through 15 days after the last dose of 
study medication. Relationship of adverse events to study 
medication (not, unlikely, possibly, or probably related) 
and intensity (mild, moderate, or severe) were determined 
by the investigator. Serious adverse events were defined 
as an adverse event that was immediately life-threatening, 
resulted in or prolonged inpatient hospitalization, resulted 
in death or permanent or substantial disability, was a con-
genital anomaly/birth defect, or might have jeopardized the 
subject and required medical intervention to prevent one of 
these outcomes. Complete physical examination was per-
formed at screening and 48 hours after the last dose of study 
  medication. Vital signs were recorded at screening, one day 
before each dose of study medication, and at specified times 
from 2–48 hours after each dose of study medication.   Clinical 
chemistry, hematology, and urinalysis were performed at 
screening, one day before the first dose of study medication, 
and 48 hours after the last dose of study medication.
statistical analysis
Pharmacokinetic parameters were analyzed in all subjects 
who received $1 dose of Oxy-ER and Oxy-CRF and were 
determined by the pharmacokineticist to have sufficient 
plasma concentration data to calculate AUC and Cmax. Phar-
macokinetic data from subjects who had vomited within the 
first 12 hours of a treatment period were not analyzed. For 
calculation of mean concentrations, values below the limit of 
quantification were set to 0 or, if occurring between two other 
such concentrations, were indicated as missing. For calcula-
tion of pharmacokinetic parameters, plasma concentrations 
below the limit of quantification were set to 0 if occurring 
before the first measurable concentration and otherwise were 
indicated as missing.
Pharmacokinetic parameters were summarized descrip-
tively, using the number of subjects, mean, standard deviation, 
and coefficient of variation (AUC0–t, AUC0–inf, Cmax, and t1/2) 
or the median and range (tmax). Repeated measures analysis 
of variance with treatment as the fixed factor and subject 
within-treatment sequence as a random factor was performed 
on the log-transformed values for AUC0–t, AUC0–inf, and Cmax. 
Geometric mean ratios (Oxy-CRF/Oxy-ER) and 90% con-
fidence intervals (CI) were calculated by the antilog of the 
least squares mean differences and their CIs. The criterion 
for bioequivalence was met if the 90% CIs of the geometric 
mean ratio (Oxy-CRF/Oxy-ER) for oxymorphone AUC0–t, 
AUC0–inf, and Cmax were within 0.8–1.25.
The safety population comprised all subjects who 
received $1 dose of Oxy-ER, Oxy-CRF, or naltrexone. 
Safety variables were summarized by treatment and using 
appropriate descriptive statistics.
SAS® (version 9.2, SAS Institute Inc, Cary, NC) was used 
for all analyses. A sample size of 26 subjects was planned for 
each study. Assuming an intrasubject coefficient of variation 
of 30.2% for oxymorphone, and allowing for a 5% difference 
between treatment groups, this sample size would provide 
$90% power to demonstrate bioequivalence using this rep-
licated dosing design.
Results
subject disposition and characteristics
Subject disposition is shown in Figure 1. In study 1, 2, and 3, 
there were 30, 37, and 36 subjects enrolled and included in the 
safety population and 28, 30, and 29 subjects who completed 
the study, respectively. In study 1 (5 mg, fasted), two   subjects Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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were excluded from the pharmacokinetics population because 
they were administered only one dose of Oxy-ER. The 
pharmacokinetics population comprised 27 subjects who 
completed the study and one who partially completed the 
study. In study 2 (40 mg, fasted), 6 subjects were excluded 
from the pharmacokinetics population because they were not 
administered any Oxy-ER or Oxy-CRF (n = 3) or because 
they were administered only one dose of Oxy-ER (n = 3). 
The pharmacokinetics population comprised all 30 subjects 
who completed the study and one who partially completed 
the study. In study 3 (40 mg, fed), six subjects were excluded 
from the pharmacokinetics population because they were not 
administered oxymorphone. The pharmacokinetics popula-
tion comprised 29 subjects who completed the study and one 
who partially completed the study.
Demographics and clinical characteristics were similar in 
the three studies (Table 1). Across the three studies, mean age 
was 33–35 years, 47%–60% of subjects were women, $78% 
were white, and mean body mass index was 25–26 kg/m2.
Plasma oxymorphone pharmacokinetics
With all doses and administration conditions (fasted or 
fed), the oxymorphone plasma concentration versus time 
profile was similar overall for Oxy-ER and   Oxy-CRF 
(Figure 2). Each profile demonstrated two distinct peaks 
at   approximately 2–3 hours and 5–6 hours after drug 
  administration, followed by a gradual decline in plasma con-
centration interrupted by a brief plateau at   approximately 
10–12 hours after drug administration. The second peak 
was generally larger than the first, but the difference was 
more notable for Oxy-CRF, which had a smaller initial peak 
than Oxy-ER. Mean oxymorphone plasma concentrations 
for Oxy-ER and Oxy-CRF were the same starting 6 (5 mg, 
fasted), 8 (40 mg, fasted), or 16 hours (40 mg, fed) after 
administration.
Study 1
(5 mg, fasted)
Study 2
(40 mg, fasted)
Study 3
(40 mg, fed)
n = 30 enrolled
n = 37 enrolled
and received
naltrexone
n = 36 enrolled
and received
naltrexone
n = 30 randomized and received
Oxy-ER or Oxy-CRF
n = 34 randomized and received
Oxy-ER or Oxy-CRF
n = 30 randomized and received
Oxy-ER or Oxy-CRF
n = 1 withdrew consent
n = 1 protocol violation
n = 1 withdrew consent
n = 1 protocol violation
n = 1 withdrawn by physician
n = 1 AE
n = 1 AE
n = 28 completed the study n = 30 completed the study n = 29 completed the study
n = 28 PK population
n = 30 safety population
n = 31 PK population
n = 37 safety population
n = 30 PK population
n = 36 safety population
Figure 1 subject disposition.
Abbreviations: Ae, adverse event; Oxy-er, oxymorphone extended release; Oxy-crF, crush-resistant oxymorphone extended release; PK, pharmacokinetics.
Table 1 subject demographics (safety population)
Characteristic Treatment
5 mg, Fasted  
(n = 30)
40 mg, Fasted  
(n = 37)
40 mg, Fed   
(n = 36)
Age, years
  Mean ± sD 
 
35 ± 7
 
33 ± 8
 
34 ± 8
  range 20–45 19–44 19–44
Women, n (%) 14 (47) 22 (59) 19 (53)
race, n (%)
  White 26 (87) 29 (78) 30 (83)
  Black 4 (13) 8 (22) 6 (17)
ethnicity, n (%)
  hispanic 30 (100) 32 (86) 36 (100)
  non-hispanic 0 5 (14) 0
height, cm 
  Mean ± sD 
 
169 ± 9
 
166 ± 9
 
167 ± 9
  range 152–187 141–184 145–185
Weight, kg 
  Mean ± sD 
 
72 ± 10
 
72 ± 10
 
71 ± 12
  range 53–95 51–95 51–96
BMi, kg/m2 
  Mean ± sD 
 
25 ± 3
 
26 ± 2
 
25 ± 3
  range 21–30 22–30 19–30
Abbreviations: BMi, body mass index; sD, standard deviation.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Figure 2 Mean oxymorphone plasma concentrations 0–48 hours after single oral doses of Oxy-er and Oxy-crF (A) 5 mg administered under fasted conditions, (B) 40 mg 
administered under fasted conditions, and (C) 40 mg administered after a high-fat breakfast.
Abbreviations: Oxy-er, oxymorphone extended release; Oxy-crF, crush-resistant oxymorphone extended release; se, standard error.
Systemic plasma oxymorphone exposure (AUC and 
Cmax) was also similar after single doses of Oxy-ER and 
Oxy-CRF (Table 2). Mean ± SD oxymorphone AUC0–t for 
Oxy-ER and   Oxy-CRF, respectively, was 5.05 ± 1.55 and 
5.29 ± 1.52 ng ⋅ h/mL after a 5 mg dose administered under 
fasted conditions, 31.51 ± 10.95 and 31.23 ± 10.33 ng ⋅ h/mL 
after a 40 mg dose administered under fasted conditions, 
and 50.16 ± 14.91 and 49.01 ± 14.03 ng ⋅ h/mL after a 40 mg 
dose administered following a high-fat breakfast. Mean ± SD 
oxymorphone Cmax for Oxy-ER and Oxy-CRF,   respectively, Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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was 0.38 ± 0.11 and 0.37 ± 0.12 ng/mL after a 5 mg dose 
administered under fasted conditions, 2.37 ± 1.20 and 
2.41 ± 0.94 ng/mL after a 40 mg dose administered under 
fasted conditions, and 5.87 ± 1.99 and 5.63 ± 2.26 ng/mL 
after a 40 mg dose administered following a high-fat 
breakfast.
Median oxymorphone tmax was the only pharmacokinetic 
parameter to differ between Oxy-ER and Oxy-CRF, being 
shorter for Oxy-ER versus Oxy-CRF 40 mg (Table 2), with 
differences of 2 hours under fasted conditions (3.0 versus 
5.0) and 1.5 hours under fed conditions (3.5   versus 5.0). 
The difference in median tmax was smaller when 5 mg 
doses of Oxy-ER and Oxy-CRF were compared (6.0   versus 
5.0 hours). The tmax values roughly corresponded to the 
time at which the two early peaks occurred in the plasma 
concentration versus time profiles (Figure 2). The range 
of tmax was similar for the two formulations in each of the 
three studies.
Plasma 6-hydroxy-oxymorphone 
pharmacokinetics
Mean plasma 6-OH-oxymorphone concentration versus time 
profiles were similar for Oxy-ER and Oxy-CRF, regardless 
of dose or administration conditions (Figure 3). Profiles 
exhibited a single peak at approximately 2–3 hours under 
fasted conditions and 5 hours under fed conditions. Starting 
6 (5 mg, fasted), 12 (40 mg, fasted), or 16 hours (40 mg, 
fed) after drug administration, mean concentrations were 
the same for Oxy-ER and Oxy-CRF. Systemic plasma 
6-OH-oxymorphone exposure did not differ between the two 
formulations (Table 3), but median tmax was 1.0 (40 mg, fed) 
to 1.5 hours (5 mg, fasted; 40 mg, fasted) shorter for Oxy-ER 
versus Oxy-CRF.
Bioequivalence
Within-subject variability in oxymorphone AUC and Cmax 
ranged from 11% to 24% and was comparable between the 
two oxymorphone formulations (data not shown). For all 
doses and under both fasted and fed conditions, the 90% CI 
for the comparisons of Oxy-ER and Oxy-CRF plasma oxy-
morphone AUC0–t, AUC0–inf, and Cmax were within 0.8–1.25 
(Table 4), fulfilling the bioequivalence criterion.   Comparisons 
of Oxy-ER and Oxy-CRF plasma 6-OH-oxymorphone were 
supportive of the finding of bioequivalence with respect to 
oxymorphone (Table 5).
safety
The  proportion  of  subjects  administered  Oxy-ER 
and Oxy-CRF, respectively, who experienced $1 
treatment-emergent adverse event was 25% (n = 7/28) and 
23% (7/30) for the 5 mg doses administered under fasted 
conditions, 9% (3/34) and 16% (5/31) for the 40 mg doses 
administered under fasted conditions, and 20% (6/30, both 
treatments) for the 40 mg doses administered under fed 
conditions. The most frequent adverse events, and the only 
adverse events that occurred in $1 subject treated with a par-
ticular dose of Oxy-ER or Oxy-CRF, were nausea, headache, 
vomiting, and dizziness. Treatment-related adverse events 
were infrequent with both formulations (range for treatment 
groups, 3%–13% of subjects). There were no severe adverse 
events, no adverse events, and no deaths. There were no clini-
cally significant changes in physical examination   findings, 
Table 2 Plasma oxymorphone pharmacokinetic parameters
Parameter Treatment
5 mg, Fasted  
(n = 28)
40 mg, Fasted  
(n = 31)
40 mg, Fed  
(n = 30)
Oxy-ER Oxy-CRF Oxy-ER Oxy-CRF Oxy-ER Oxy-CRF
AUc0–t, ng ⋅ h/mL Mean ± sD 5.05 ± 1.55 5.29 ± 1.52 31.51 ± 10.95 31.23 ± 10.33 50.16 ± 14.91 49.01 ± 14.03
  %cV 30.7 28.7 34.7 33.1 29.7 28.6
AUc0–inf, ng ⋅ h/mL Mean ± sD nD nD 32.99 ± 11.58 32.65 ± 10.92 52.29 ± 15.98 50.95 ± 14.63
  %cV 35.1 33.4 30.6 28.7
cmax, ng/mL Mean ± sD 0.38 ± 0.11 0.37 ± 0.12 2.37 ± 1.20 2.41 ± 0.94 5.87 ± 1.99 5.63 ± 2.26
  %cV 30.5 31.7 50.6 38.9 33.9 40.1
Median tmax, h 6.0 5.0 3.0 5.0 3.5 5.0
  range 1.0–12.0 1.0–16.0 0.5–12.0 0.5–12.0 1.0–6.0 1.0–10.0
Mean ± sD t1/2, ha nD nD 10.0 ± 2.5 9.9 ± 2.7 10.5 ± 4.1 10.3 ± 3.6
  %cV 25.5 26.9 39.3 35.2
Note: anot evaluated because monoexponential elimination was not evident in most cases. 
Abbreviations: AUc0–inf, area under the concentration versus time curve from time 0 to infinity; AUC0–t, AUc from time 0 to the last measured concentration; 
cmax, maximum plasma concentration; CV, coefficient of variation; ND, not determined; Oxy-CRF, crush-resistant oxymorphone extended release; Oxy-ER, oxymorphone   
extended release; t1/2, terminal half-life; tmax, time to cmax; sD, standard deviation.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Figure 3 Mean 6-Oh-oxymorphone plasma concentrations 0–48 hours after single oral doses of Oxy-er and Oxy-crF (A) 5 mg administered under fasted conditions, 
(B) 40 mg administered under fasted conditions, and (C) 40 mg administered after a high-fat breakfast.
Abbreviations: 6-Oh-oxymorphone, 6-hydroxy-oxymorphone; Oxy-er, oxymorphone extended release; Oxy-crF, crush-resistant oxymorphone extended release.
Table 3 Plasma 6-Oh-oxymorphone pharmacokinetic parameters
Parameter Treatment
5 mg, Fasted  
(n = 28)
40 mg, Fasted  
(n = 31)
40 mg, Fed  
(n = 30)
Oxy-ER Oxy-CRF Oxy-ER Oxy-CRF Oxy-ER Oxy-CRF
AUc0–t, ng ⋅ h/mL Mean ± sD 4.15 ± 1.82 4.24 ± 1.95 26.08 ± 9.39 26.10 ± 10.18 33.40 ± 11.94 33.39 ± 11.48
  %cV 43.9 46.0 36.0 39.0 35.7 34.4
AUc0–inf, ng ⋅ h/mL Mean ± sD nD nD 32.96 ± 13.86 33.61 ± 15.57 40.99 ± 16.47 42.05 ± 16.88
  %cV 42.1 46.3 40.2 40.1
cmax, ng/mL Mean ± sD 0.24 ± 0.07 0.20 ± 0.12 1.61 ± 0.59 1.45 ± 0.55 2.24 ± 0.89 2.23 ± 0.87
  %cV 28.2 56.9 36.3 37.6 39.7 38.8
Median tmax, h 1.5 3.0 1.5 3.0 4.0 5.0
  range 0.5–6.0 0.5–24.0 0.5–5.0 0.5–24.0 1.0–10.0 1.0–12.0
Mean ± sD t1/2, ha nD nD 19.3 ± 9.8 21.5 ± 15.9 17.8 ± 7.3 19.5 ± 8.8
  %cV 50.8 73.7 41.1 45.0
Note: anot evaluated because monoexponential elimination was not evident in most cases. 
Abbreviations: 6-Oh-oxymorphone, 6-hydroxy-oxymorphone;  AUc0–inf, area under the concentration versus time curve from time 0 to infinity;  AUC0–t,  AUc from time 
0 to the last measured concentration; cmax, maximum plasma concentration; CV, coefficient of variation; ND, not determined; Oxy-CRF, crush-resistant oxymorphone extended 
release; Oxy-er, oxymorphone extended release; t1/2, terminal half-life; tmax, time to cmax.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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vital signs, or laboratory findings that were deemed to be 
related to treatment.
Discussion
These three randomized clinical trials evaluated the bioequiv-
alence of the lowest (5 mg) and highest (40 mg) supplied 
dosage strengths of Oxy-ER and the same doses of Oxy-CRF 
in healthy adults under fasted (5 mg, 40 mg) and fed (40 mg) 
conditions. Oxy-ER and Oxy-CRF demonstrated overall 
similar oxymorphone and 6-OH-oxymorphone plasma con-
centrations over time. Differences in tmax between Oxy-ER 
and Oxy-CRF were not clinically relevant. The criterion for 
bioequivalence of plasma oxymorphone exposure was met for 
all parameters (AUC0–t, AUC0–inf, Cmax). In these subjects, most 
of whom also received naltrexone, Oxy-ER and Oxy-CRF 
were generally well tolerated, with no discernable differences 
between formulations.
Findings were consistent overall for oxymorphone 
and its active metabolite, 6-OH-oxymorphone. For 
  6-OH-oxymorphone, overall systemic plasma exposure, 
as indicated by the AUC0–t, did not differ between the two 
formulations, and data were supportive of the finding of 
bioequivalence with respect to oxymorphone.
In the 40 mg dose studies, naltrexone was administered 
at the beginning of each treatment period to limit opioid-
related adverse events. Although naltrexone is reported 
to increase oxymorphone peak plasma exposure (data on 
file, Endo Pharmaceuticals Inc), naltrexone administra-
tion in the current study is not likely to have affected 
the evaluation of bioequivalence because dose and time 
of administration were standardized across subjects and 
treatment periods.
The presence of peaks and shoulders in the concentration 
versus time curves has been observed in previous studies 
(data on file, Endo Pharmaceuticals Inc). The timing of the 
later peaks often corresponds with eating and may be related 
to the known increase in systemic exposure to oxymorphone 
when administered with food,5 combined with prolonged 
absorption from these formulations.
The bioequivalence findings indicate a 1:1 correspon-
dence between doses of Oxy-ER and Oxy-CRF. This would 
facilitate conversion from Oxy-ER to Oxy-CRF. In addition, 
the ratios for conversion of other oral opioid doses to Oxy-ER 
can be considered appropriate for Oxy-CRF.5
Study subjects were selected to satisfy US Food and 
Drug Administration guidelines for bioequivalence studies8 
and not to represent the clinical population that would be 
using oxymorphone. Moreover, subjects treated with 40 mg 
doses also received naltrexone. Thus, the safety profile was 
not the same as in patients or healthy subjects not receiving 
an opioid antagonist. However, Oxy-ER and Oxy-CRF had 
a similar safety profile for subjects administered an opioid 
antagonist (ie, naltrexone) along with an opioid. There were 
no important differences in the type or frequency of adverse 
events, regardless of dose or condition of administration 
(fasted or fed). There was also no indication of new adverse 
events or an increase in the frequency of adverse events with 
Oxy-CRF versus Oxy-ER.
The efficacy and safety of Oxy-ER have been demon-
strated in randomized controlled trials of up to 12 weeks 
and extension trials of up to one year in opioid-naive and 
Table 4   Bioequivalence  data:  systemic  plasma  oxymorphone 
exposure
Parameter Ratio of least squares  
geometric means  
(Oxy-CRF/Oxy-ER)
90% CI
5 mg, fasted
  AUc0–t, ng ⋅ h/mL 1.05 1.01–1.09
 c max, ng/mL 0.98 0.93–1.03
40 mg, fasted
  AUc0–t, ng ⋅ h/mL 0.99 0.95–1.04
  AUc0–inf, ng ⋅ h/mL 0.99 0.95–1.04
 c max, ng/mL 1.05 0.98–1.12
40 mg, fed
  AUc0–t, ng ⋅ h/mL 0.97 0.93–1.02
  AUc0–inf, ng ⋅ h/mL 0.97 0.93–1.02
 c max, ng/mL 0.94 0.88–1.02
Abbreviations: AUc0–inf, area under the concentration versus time curve from 
time 0 to infinity; AUC0–t, AUc from time 0 to the last measured concentration;   
cmax,  maximum  plasma  concentration;  Oxy-crF,  crush-resistant  oxymorphone 
extended release; Oxy-ER, oxymorphone extended release; CI, confidence interval.
Table 5 Bioequivalence data: systemic plasma 6-Oh-oxymorphone 
exposure
Parameter Ratio of least squares mean,  
Oxy-CRF/Oxy-ER
90% CI
5 mg, fasted
  AUc0–t, ng ⋅ h/mL 1.01 0.95–1.07
 c max, ng/mL 0.80 0.75–0.86
40 mg, fasted
  AUc0–t, ng ⋅ h/mL 0.99 0.94–1.04
  AUc0–inf, ng ⋅ h/mL 1.01 0.95–1.08
 c max, ng/mL 0.91 0.86–0.95
40 mg, fed
  AUc0–t, ng ⋅ h/mL 1.00 0.96–1.05
  AUc0–inf, ng ⋅ h/mL 1.02 0.97–1.08
 c max, ng/mL 1.01 0.94–1.07
Abbreviations:  6-Oh-oxymorphone,  6-hydroxy-oxymorphone;  AUc0–inf,  area 
under the concentration versus time curve from time 0 to infinity; AUC0–t, AUc from 
time 0 to the last measured concentration; cmax, maximum plasma concentration; 
Oxy-crF, crush-resistant oxymorphone extended release; Oxy-er, oxymorphone 
extended release; CI, confidence interval.Drug Design, Development and Therapy
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er versus crush-resistant er oxymorphone
opioid-experienced patients with moderate to severe chronic 
low back pain,9,10 cancer pain,11,12 and osteoarthritis.13,14 
Other benefits are the low potential for drug–drug interac-
tions   (oxymorphone does not inhibit cytochrome P450 
enzymes)15 and simplified interpretation of urine testing 
(oxymorphone does not produce any metabolites that can be 
mistaken for another prescribed drug).16 The bioequivalence 
findings of the studies reported here indicate that Oxy-CRF 
is expected to have clinical efficacy and safety equivalent 
to Oxy-ER.
Conclusion
Three randomized clinical trials demonstrated bioequivalence 
of Oxy-ER and Oxy-CRF 5 mg under fasted conditions and 
40 mg under fasted and fed conditions. The treatments had 
similar safety profiles and were generally well tolerated, given 
that most subjects also received naltrexone.
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